Last reviewed · How we verify
NCT05948605
EMPOWER AUD Pivotal Trial
NA trial testing Empower Neuromodulation System in Alcoholism in 35 participants. Completed in 6 August 2025.
6 August 2025
Quick facts
| Lead sponsor | Theranova, L.L.C. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 1 December 2023 |
| Primary completion | 6 August 2025 |
| Estimated completion | 6 August 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Empower Neuromodulation System
Conditions studied
- Alcoholism — all drugs for Alcoholism →
- Alcohol Abuse — all drugs for Alcohol Abuse →
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Sponsor
Theranova, L.L.C.
Who can join
21 and older, any sex, with Alcoholism or Alcohol Abuse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multi-site, double-blinded, prospective, randomized, sham-controlled study
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05948605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Empower Neuromodulation System
Trials testing the same drug.
- NCT04901481 — Empower Neuromodulation System - Pilot Study for Anxiety Treatment · NA · terminated
- NCT04244227 — Pilot Research on Opioid Use Disorder · NA · active not recruiting
- NCT03983317 — Pilot Evaluation of the Empower Neuromodulation System in AUD Patients · NA · completed
Other recruiting trials for Alcoholism
Currently open trials in the same condition.
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06493773 — Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial · NA · recruiting
- NCT07216872 — Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use · NA · recruiting
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
- NCT06415721 — Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder · NA · recruiting
Other Theranova, L.L.C. trials
Trials by the same sponsor.
- NCT06760572 — Airway Data Collection With the Entarik Feeding Tube System · NA · recruiting
- NCT05162833 — Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms · NA · completed
- NCT04758247 — Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms · NA · completed
- NCT04901481 — Empower Neuromodulation System - Pilot Study for Anxiety Treatment · NA · terminated
- NCT04166045 — Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05948605 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Theranova, L.L.C.
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05948605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing